Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers

发表于 2026-9-29 12:01:21

期刊：Journal of Medicinal Chemistry

文献作者：James Cregg; Anne V. Edwards; Stephanie Chang; Bianca J. Lee; John E. Knox; Aidan C. A. Tomlinson; Abby Marquez; Yang Liu; Rebecca Freilich; Naing Aay; Yingyun Wang; Lingyan Jiang; Jingjing Jiang; Zhican Wang; Michael Flagella; David Wildes; Jacqueline A.M. Smith; Mallika Singh; Zhengping Wang; Adrian L. Gill; Elena S. Koltun

出版日期：2025-3-27

DOI号：10.1021/acs.jmedchem.4c02314

下载链接：https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c02314

文献链接：https://doi.org/10.1021/acs.jmedchem.4c02314

当前文献来源于 American Chemical Society (ACS)。

备注信息：

发表于 2026-9-29 12:01:22

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[ACS] Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ACS] Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers 一键复制